APOE and atherosclerosis: There has been some concern about the possibility that mirabregon administration could potentiate the development of atherosclerosis and associated cardiovascular diseases, generated from the analysis of preclinical data obtained from murine models (mice genetically deficient in apolipoprotein E or LDL receptor) (Sui et al., 2019).